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OBSERVATIMolecular Analyses Define Va7.2-Ja33þ MAIT
Cell Depletion in HIV Infection
A Case–Control Study
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cell population is unlikely. Molecular approaches represent a suitable
alternative to flow cytometry-based assays for tracking of MAIT cells in
HIV and other settings.
in all these studies13–18
TCR, but in combina
identifies MAIT cells
Editor: Vivek Naranbhai.
Received: April 2, 2015; revised: June 15, 2015; accepted: June 17, 2015.
From the Peter Medawar Building for Pathogen Research (JEU, PP, CC,
PG, REP, CBW, PK), University of Oxford, Oxford, UK; Department of
Microbiology and Immunology (JEU, RFH), University of Otago, Dunedin,
New Zealand; Ragon Institute of MGH, MIT and Harvard (CC),
Cambridge, Massachusetts, USA; Division of Infectious Diseases (AR),
University Hospital Berne and University of Berne, Berne; Division of
Infectious Diseases and Hospital Epidemiology and Institute of Medical
Virology (HFG), University Hospital Zurich, University of Zurich, Zurich,
Switzerland.
Correspondence: Dr James E. Ussher, Department of Microbiology and
Immunology, University of Otago, PO Box 56, Dunedin 9054, New
Zealand (e-mail: james.ussher@otago.ac.nz).
This work was funded by the Wellcome Trust (WT091663MA), the Oxford
Dominions Trust, and the Swiss HIV Cohort Study, which is supported
by the Swiss National Science Foundation (grant # 148522) and by
SHCS project 671. The data for the Swiss HIV Cohort Study are gathered
by the Five Swiss University Hospitals, 2 Cantonal Hospitals, 15
affiliated hospitals, and 36 private physicians (listed in http://
www.shcs.ch/31-health-care-providers). The members of the SHCS
are listed under the ‘‘Acknowledgments’’ and also available at http://
www.shcs.ch/184-for-shcs-publications.
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000001134
Medicine  Volume 94, Number 29, July 2015h F. Gu¨nthard
MBBS, DPhil,Christian B. Willberg, DPhil, an
Abstract: Mucosal-associated invariant T (MAIT) cells are an abun-
dant antibacterial innate-like lymphocyte population. There are con-
flicting reports as to their fate in HIV infection. The objective of this
study was to determine whether MAIT cells are truly depleted in HIV
infection.
In this case-control study of HIV-positive patients and healthy
controls, quantitative real-time polymerase chain reaction was used
to assess the abundance of messenger RNA (mRNA) and genomic DNA
(gDNA) encoding the canonical MAIT cell T cell receptor (Va7.2-
Ja33). Comparison was made with flow cytometry.
Significant depletion of both Va7.2-Ja33 mRNA and gDNA was
seen in HIV infection. Depletion of Va7.2þCD161þþ T cells was
confirmed by flow cytometry. In HIV infection, the abundance of
Va7.2-Ja33 mRNA correlated most strongly with the frequency of
Va7.2þCD161þþ cells. No increase was observed in the frequency of
Va7.2þCD161 cells among CD3þCD4 lymphocytes.
MAIT cells are depleted from blood in HIV infection as confirmed
by independent assays. Significant accumulation of a CD161 MAITodney E. Phillips,
aul Klenerman, BMBCh, DPhil
(Medicine 94(29):e1134)
Abbreviations: B2M = b2-microglobulin, CT = threshold cycle,
Ca = constant region of the T-cell receptor alpha chain, gDNA =
genomic DNA, HC = healthy control, Ja = junctional region of the
T-cell receptor alpha chain, MAIT cells = mucosal-associated
invariant T cells, MR1 = major histocompatibility complex, class I
related, mRNA = messenger RNA, PCR = polymerase chain
reaction, RNA = ribonucleic acid, RT-PCR = reverse transcription
polymerase chain reaction, TCR = T-cell receptor, Va = variable
region of the T-cell receptor alpha chain.
INTRODUCTION
M ucosal-associated invariant T (MAIT) cells are innate-like T cells that comprise5% of the T-cell population in
adult blood and are further enriched in mucosal and liver
tissues.1–3 MAIT cells are restricted by the nonpolymorphic,
highly evolutionarily conserved major histocompatibility com-
plex, class Ib-related protein (MR1).2 MR1 has recently been
shown to present a metabolite derived from the riboflavin
synthetic pathway.4,5 Consistent with this, MAIT cells are
activated by riboflavin-producing bacteria, includingMycobac-
terium tuberculosis, Escherichia coli, and Salmonella
species.6,7 MAIT cells have also been shown to protect against
bacterial infection in vivo, including against dissemination of
bacillus Calmette–Guerin (BCG) in a mouse model.8
MAIT cells have a semiinvariant T-cell receptor (TCR),
Va7.2-Ja33, and utilize a limited range of Vb chains.9
Additional minor MR1-restricted MAIT cell populations with
Va7.2-Ja20 and Va7.2-Ja12 have recently been described
through use of an MR1 tetramer.10 MAIT cells are defined
by high levels of expression of the C-type lectin, CD161.3 More
than 90% of MAIT cells are CD8aþ, whereas 7% are CD4/
CD8 double negative and <1% are CD4þ.11 MAIT cells also
express high levels of the interleukin (IL)-18 receptor and are
able to make interferon-g in response to IL-12 and IL-18 in the
absence of TCR stimulation.12
Recently, several reports have identified a significant impact
ofHIV infection onMAIT cells.13–18Although all studies show a
loss ofCD161þþVa7.2þMAITcells, it has been suggested that
MAIT cells downregulate CD161 after activation and that inHIV
infection the frequency of MAIT cells (including both
CD161þþVa7.2þ and CD161Va7.2þ MAIT cells) is
unchanged.14 Importantly, theVa7.2 antibody (clone 3C10) usedis not specific for the canonicalMAIT cell
tion with CD161 expression accurately
.3 Therefore, we sought to determine
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whether MAIT cells were preserved or depleted in HIV through
quantitative real-time polymerase chain reaction (PCR) for the
canonical MAIT cell TCR, Va7.2-Ja33.
METHODS
Blood Samples
Leukocyte cones from unidentified healthy controls (HCs)
(n¼ 38) were obtained from NHS Blood and Transplant. Blood
was obtained from HIV-infected patients (HIVþ) in the Thames
Valley (n¼ 26)19 and Swiss HIV cohorts (n¼ 20) or HCs
(n¼ 12). Peripheral blood mononuclear cells (PBMCs) were
purified on Lymphoprep gradients,13 and cryopreserved prior
to analysis. Clinical details of patients in the Thames Valley
cohort are shown in Table 1. Clinical details of the patients in the
Swiss HIV cohort have previously been reported,13 and are re-
presented here in Table 1.
Written, informed consent was given by participants. The
collection of samples was approved by the relevant ethics
committees (the Central University Research Ethics Committee
at the University of Oxford and the relevant ethics committees at
all the participating institutions in Switzerland).
Quantitative Real-Time Reverse Transcription-PCR
RNAwas extracted from PBMCs (13 HCs, 15 HIVþ) using
the MiniRNA extraction kit (Qiagen, Hilden, Germany) or, in
sorting experiments, theNucleoSpin RNA isolation kit (Machery
Nagel, Bethlehem, PA, USA), as per the manufacturer’s instruc-
tionswith on-columnDNase digestion. Reverse transcriptionwas
performed with Superscript III using a mix of anchored oli-
go(dT)20 primers (0.625mg) and random primers (2.25mg)
(all Life Technologies, Carlsbad, CA, USA) as per the manu-
facturer’s instructions. Samples were then incubated with 2U of
RNAseH (Life Technologies, Carlsbad, CA,USA) for 20minutes
at 37oC before use in a real-time PCR. In sorting experiments,
high-capacity RNA-to-cDNA kit (Life Technologies, Carlsbad,
CA, USA) was used as per the manufacturer’s instructions.
Genomic DNA Extraction
GenomicDNA (gDNA)was extracted fromwhole blood (12
HCs, 11 HIVþ) or PBMCs (10 HCs) as previously described.20
The samevolume of elutedDNAextracted from the samevolume
Ussher et alof blood was used for quantitative real-time PCR. In sorting
experiments, the PureLink Genomic DNA Mini Kit (Life Tech-
nologies, Carlsbad, CA, USA) was used.
TABLE 1. Clinical Characteristics of HIVþ Cohorts
Chronic HIVþ (PBMC) Chronic H
n 15 1
Sex
Male 9 (60%)
Female 6 (40%)
Age
Median (P25, P75) 37 (33, 48) 3
CD4 count (cells/mL)
Median (P25, P75) 505 (432.5, 665)

47
Viral load (log10 copies/mL)
Median (P25, P75) 4.32 (3.29, 4.72)

3.7
PBMC¼ peripheral blood mononuclear cells.
Data not available for 3 patients.
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Quantitative PCR was performed on complementary DNA
or gDNA. Va7.2-Ja33 and Ca were amplified in singleplex
reactions using previously described primers (Life Technol-
ogies, Carlsbad, CA, USA) and Taqman probes (Fluorophore:
6FAM, Quencher: BQX [Sigma-Aldrich, St Louis, MO, USA]).9
For sorting experiments, the b2-microglobulin (B2M) forward
primer (GTGCTGTCTCCATGTTTGATG), reverse primer
(TCTGCTCCCCACCTCTAAG), and probe (6-FAM/AGGTT
GCTC/ZEN/CACAGGTAGCTCTAGG/Iowa Black FQ) (all Inte-
grated DNATechnologies, Coralville, IA, USA) were used.
Briefly, primers were added at a final concentration of
200 nM,Taqmanprobes at 250 nM, and FastStartUniversal Probe
Mastermix (Roche, Mannheim, Germany) or, in sorting exper-
iments, KAPA PROBE FAST qPCR Master Mix (2X) Universal
Kit (Kapa Biosystems, Wilmington, MA, USA) was used. PCR
was performed on a LC480 (Roche, Mannheim, Germany) or, in
sorting experiments, an ABI 7500 Fast (Applied Biosystems,
Foster City, CA, USA), using the following cycling conditions:
95oC for 5 minutes, then 40 cycles of 94oC for 10 seconds, 58oC
for 30 seconds, and 72oC for 10 seconds, then 408C for 10 sec-
onds. CP/CT was automatically determined by the instrument’s
software. The expression of Va7.2-Ja33 relative to Ca (or B2M)
was determined by the comparative CT method (2
DDCT). The
efficiencies of the various PCR reactions are shown in the
Supplementary Figure 1, http://links.lww.com/MD/A337.
Flow Cytometry
The following antibodies were used: Va7.2-PE, CD3-
PECy7 (BioLegend, San Diego, CA, USA), CD4-VioGreen,
CD161-APC (Miltenyi Biotec, Bergisch Gladbach, Germany),
CD4-APCeFluor780, CD8-eFluor450 (eBiosciences, San
Diego, CA, USA), CD3-Pacific Orange (Life Technologies,
Carlsbad, CA, USA), CD8-PECy7 (BD Biosciences, San Jose,
CA, USA). All samples were stained with Live/Dead Fixable
Near IR dye (Life Technologies, Carlsbad, CA, USA). Samples
were stained as previously described.13 Flow cytometry
was performed on a MACSQuant (Miltenyi Biotec, Bergisch
Gladbach, Germany), an LSRII (BD Biosciences, San Jose,
CA, USA), or for sorting experiments, on a FACSAria (BD
Biosciences, San Jose, CA, USA). Samples were gated on
lymphocytes/alive/CD3þ or lymphoctyes/alive/CD3þ/CD4
Medicine  Volume 94, Number 29, July 2015(Supplementary Figure 2, http://links.lww.com/MD/A337).
Analysis was performed in FlowJo 9.6 (Treestar, Inc., San
Carlos, CA, USA).
IVþ (Whole Blood) Swiss HIVþ Cohort (Pretreatment)
1 29
5 (45%) 26 (90%)
6 (55%) 3 (10%)
4 (33, 47) 40 (34.5, 44.5)
0 (445, 690) 202 (187, 299.5)
7 (3.58, 4.92) 4.64 (4.09, 4.99)
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Statistical Analysis
No formal power calculation was performed. Data were
analyzed in Prism 6 (GraphPad Software, San Diego, CA,
USA). Medians and all data points are shown. Comparisons
between groups were made by t tests with log10-normalized
data. For comparison of CT values, nonnormalized data was
used. For sorting experiments, a paired t test on log10 normal-
ized data was performed. Spearman correlations were calcu-
lated separately for HIVþ and HC cohorts. Significance was
defined as 2-sided P 0.05.
RESULTS
The Va7.2 antibody not only recognizes MAIT cells,
which express the canonical Va7.2-Ja33 TCR, but also other
non-MAIT cell TCRs. Therefore, we sought to determine the
number of MAIT cells in blood from HIV-infected and HIV-
uninfected donors by quantitative real-time reverse transcrip-
tion (RT)-PCR. The expression of Va7.2-Ja33 relative to the
Ca chain, which is expressed in all ab T cells, was determined.
Va7.2-Ja33 messenger RNA (mRNA) was significantly less
abundant in the blood of patients with HIV than uninfected
controls (median relative expression of Va7.2-Ja33:Ca
0.00165 vs 0.00478, P¼ 0.006) (Figure 1).
ToconfirmMAITcell depletionat the cellular level, the same
PBMCs were analyzed by flow cytometry. Frequencies were
determined as a proportion of CD3þ lymphocytes (Figure 2A).
No difference in frequency of Va7.2þ T cells was seen
(Figure 2B). Va7.2þCD161þþ cells were depleted (0.41% vs
1.93%, P¼ 0.001) (Figure 2C) whereas Va7.2þCD161 cells
were increased (2.52% vs 1.52%, P< 0.001) in HIV-infected
patients compared with HCs (Figure 2D).
As depletion of CD4þ T cells in HIV distorts relative
frequencies of other populations, and <1% of MAIT cells are
CD4þ,11 frequencies were also determined as a proportion of
CD3þCD4 lymphocytes (Figure 2E). Va7.2þ cells were
depleted in HIV-infected patients compared with HCs as a
proportion of CD3þCD4 lymphocytes (4.27% vs 8.82%,
Medicine  Volume 94, Number 29, July 2015P¼ 0.021) (Figure 2F). In HIV-infected patients versus HC,
Va7.2þCD161þþ cells were significantly depleted (0.60% vs
4.59%, P< 0.001) (Figure 2G), but no significant increase in
HC HIV
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FIGURE 1. Depletion of Va7.2-Ja33 messenger RNA from the
blood in HIV infection. The frequency of MAIT cells in blood from
HCs (open circles) or HIV-infected patients (filled circles) was
determined by quantitative real-time reverse transcription PCR.
HC¼healthy control, MAIT¼mucosal-associated invariant T,
PCR¼polymerase chain reaction.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Va7.2þCD161 cells was seen (3.69% vs 2.7%, P¼ 0.053)
(Figure 2H).
Next we determined which flow cytometric measure best
correlated with the frequency of MAIT cells, as determined by
quantitative RT-PCR. When CD4þ cells were included, there
was no significant correlationbetweenVa7.2-Ja33mRNA levels
and frequency of Va7.2þ T cells (r¼ 0.19, P¼ 0.49) in HIV-
infected patients (Figure 2I). In contrast, Va7.2-Ja33 mRNA
levels in HCs were significantly correlated with frequency of
Va7.2þ T cells (r¼ 0.85, P< 0.001) (Figure 2I). The frequency
of Va7.2þCD161þþCD3þ cells significantly correlated with
Va7.2-Ja33 mRNA levels in HIV-infected patients (r¼ 0.90,
P< 0.001) and HCs (r¼ 0.81, P¼ 0.001) (Figure 2J).
When CD4þ cells were excluded, the frequency of
Va7.2þ cells among CD3þCD4- lymphocytes correlated sig-
nificantly with Va7.2-Ja33 mRNA levels in HC (r¼ 0.78,
p¼ 0.003) but not HIV-infected patients (r¼ 0.38, p¼ 0.17)
(data not shown). The frequency of Va7.2þCD161þþ cells
amongst CD3þCD4- lymphocytes correlated significantly with
Va7.2-Ja33 mRNA levels in both groups (HIVþ: r¼ 0.90,
p< 0.001; HC: r¼ 0.78, p¼ 0.003) (Figure 2K). Therefore, in
HIV infection frequency of Va7.2þCD161þþ cells most
accurately reflects abundance of MAIT cells.
To confirm that MAIT cells are depleted in HIV infection
and that Va7.2þCD161 cells are not significantly enriched,
we reanalyzed our previously published data from the Swiss
HIV Cohort Study excluding CD4þ T cells.13 Comparison of
the pretreatment timepoint with HCs demonstrated a significant
depletion of Va7.2þCD161þþ cells as a proportion of
CD3þCD4 lymphocytes (1.10% vs 4.59% in HIVþ vs HC,
P¼ 0.002) (Figure 3A). No significant difference was seen in
the proportion of Va7.2þCD161 cells (median 2.77% vs
2.65% in HIVþ vs HC, P¼ 0.073) (Figure 3B).
As a selective downregulation ofMAITcell TCRexpression
could account for the apparent decrease in Va7.2-Ja33 mRNA
abundance relative to Ca mRNA in HIV infection, we investi-
gated whether MAIT cell gDNA was also depleted from blood.
This is possible because during TCR rearrangement, the variable
and junctional regions are joined together to form a single exon.21
Using PBMCs from HC, we first confirmed that Va7.2-Ja33
gDNA abundance correlated with Va7.2-Ja33 mRNA abun-
dance; as expected, a significant correlation was found
(r¼ 0.78, P¼ 0.01) (Figure 4A). Furthermore, Va7.2-Ja33
gDNA abundance was strongly correlated with the frequency
of Va7.2þCD161þþ cells among CD3þ lymphocytes
(r¼ 0.94,P< 0.001) (Figure 4B). Therefore, Va7.2-Ja33 gDNA
abundance is a validmeasure of absoluteMAIT cell numbers.We
measured the abundance of Va7.2-Ja33 gDNA in a different
cohort of HIV-infected patients and compared it with HC. Con-
sistent with the decreased relative abundance of Va7.2-Ja33
mRNA (Figure 1), there was a significant decrease in the relative
abundance of Va7.2-Ja33 gDNA (median abundance of the
Va7.2-Ja33 rearrangement relative to Ca 0.00344 vs 0.00061,
P< 0.001) in HIVþ versus HCs (Figure 4C). As DNA was
extracted from equal volumes of blood and equal volumes of
extracted DNA were used as the template for PCR, CT could be
used as a direct measure of MAIT cell abundance per volume of
blood. The CT for Va7.2-Ja33 was significantly higher (median
CT 30.93 vs 28.05, P< 0.001) in HIVþ versus HC (Figure 4D),
confirming absolute depletion of the MAIT cell population.
To confirm the specificity of the PCR, RNA and
MAIT Cell Quantitative PCR in HIV InfectionDNA were extracted from FACS-sorted MAIT cells
(Va7.2þCD161þþCD8þCD3þ lymphocytes) and non-MAIT
cells (Va7.2-CD161CD3þ lymphocytes). The relative
www.md-journal.com | 3
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FIGURE 2. MAIT cells are depleted in the blood of HIV-infected patients. The frequency of MAIT cells in blood from HCs (open circles) or
HIV-infected patients (filled circles) was determined by flow cytometry. (A, E) Representative plots and (B, F) cumulative data of the relative
frequencies of the Va7.2þ, (C, G) Va7.2þCD161þþ, and (D, H) Va7.2þCD161 populations among (A–D) CD3þ lymphocytes and (E–
H) CD3þCD4 lymphocytes in HC and HIV-infected patients is shown. Correlation of the frequency of (I) Va7.2þCD3þ cells, (J)
Va7.2þCD161þþCD3þ cells, or (K) Va7.2þCD161þþCD3þCD4 cells, as assessed by flow cytometry, with the abundance of MAIT
cells, as assessed by quantitative real-time RT-PCR. Spearman correlations were calculated separately for HIV-infected patients and for HCs.
The same samples were analyzed in Figures 1 and 2. HC¼healthy control, MAIT¼mucosal-associated invariant T, RT-PCR¼ reverse
transcription polymerase chain reaction.
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Medicine  Volume 94, Number 29, July 2015 MAIT Cell Quantitative PCR in HIV Infectionexpression of Va7.2-Ja33 mRNA was 406-fold enriched
(Figure 4E) and the Va7.2-Ja33 gDNA rearrangement was
743-fold enriched (Figure 4F) in the sorted MAIT cell popu-
lation. These results were consistent with the sort purity (MAIT
cells: 94% Va7.2þCD161þþCD3þ; non-MAIT cells:
<0.01% Va7.2þCD161þþCD3þ).
Finally, we assessed whether the relative abundance of
Va7.2-Ja33 mRNA or gDNA correlated with HIV viral load
(open circles) or HIV-infected patients (filled circles) was determined
(A) Va7.2þCD161þþ and (B) Va7.2þCD161 populations among
HC¼healthy control, MAIT¼mucosal-associated invariant T.and CD4þ T-cell count. As in our previous study,13 no con-
sistent correlation was found (Supplementary Figure 2, http://
links.lww.com/MD/A337).
DISCUSSION
We have confirmed the loss of MAIT cells in blood in HIV
by molecular and flow cytometric approaches. In HIV,
decreased abundance of both Va7.2-Ja33 mRNA and gDNA
was seen. Abundance of Va7.2-Ja33 mRNA correlated most
strongly with the frequency of Va7.2þCD161þþ cells, irre-
spective of whether CD4þ T cells were included. Furthermore,
no significant increase in frequency of Va7.2þCD161 cells
was seen among CD3þCD4 lymphocytes.
A limitation of our study is that demographic data of HCs
were not available. Therefore, age and sex cannot be excluded
as confounding variables. It has recently been reported that the
frequency of MAIT cells in blood is significantly lower in older
(age 61–92 years) than younger (age 21–40 years) individ-
uals.22 However, given the low median age of the HIV-infected
cohorts in our study (Table 1), age is unlikely to explain the
differences observed.
Loss of Va7.2þþCD161þþMAIT cells in HIV infection
has previously been reported.13–16 One potential mechanism for
this is through downregulation of CD161, resulting in a change
in phenotype rather than loss of TCRþ cells.14 Indeed, in vitro
MAIT cells downregulate CD161 upon activation.14,23 Given
the disrupted intestinal epithelial integrity in HIV infection and
the subsequent translocation of bacteria,13,24–26 activation of
MAIT cells and subsequent downregulation of CD161 would be
expected. However, our study suggests that the loss of
Va7.2þCD161þþ MAIT cells in HIV infection cannot be
solely explained by downregulation of CD161. In HIV-infected
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.patients, the reduced abundance of Va7.2-Ja33 mRNA and
gDNA, the unchanged frequency of Va7.2þCD161 cells
among CD3þCD4 lymphocytes (despite the loss of
Va7.2þCD161þþ cells, which would be expected to increase
the relative frequency of this population), and the strong
correlation of Va7.2-Ja33 mRNA levels with the frequency
of Va7.2þCD161þþ cells but not total Va7.2þ cells, all argue
that MAIT cells are lost from the blood in HIV infection.
Althoughour data does not exclude thepresence ofCD161
MAIT cells in blood in HIV infection, 2 recent studies, 1 in
healthy donors and 1 in HIV-infected patients, found that MR1-
tetramer-positive cells were not present in the CD161 compart-
ment,10,17 confirming CD161 as a key marker. Furthermore,
despite an increase in frequency of Va7.2þCD161CD3þ cells
as a percentage of CD3þ cells, no increase was seen in the
number of Va7.2þCD161CD3þ cells per microliter.17,18 This
could be further investigated in future studies by quantifying the
number of MAIT cell TCR transcripts in flow cytometry-sorted
Va7.2þCD161 cells from the blood of HIV-infected patients.
Activation-induced cell death secondary to microbial
translocation and/or sequestration in tissues are alternative
explanations that have been suggested for the loss of MAIT
cells from the blood in HIV infection.13,18 We have previously
reported that in the colon, the absolute number of
MDR1þþCD3þCD8þ T cells, a proxy for MAIT cells, was
unchanged in HIV as assessed by immunohistochemistry.13
Similarly, no depletion of Va7.2þCD161þþCD3þ cells
was seen in rectal biopsies as measured by flow cytometry.14
In contrast, it was recently reported that MAIT cells (defined as
CD161þþCD8þCD3þ cells) were depleted as a proportion of
CD8þCD3þ lymphocytes in the colon in HIV, with subsequent
recovery after a median of 72 months of antiretroviral therapy.27
Interestingly, blood MAIT cell frequencies fail to recover with
antiretroviral therapy13,14 raising the possibility that recovery
occurs first in the colon27 and later in the blood. Recovery in
blood should therefore be assessed over a longer follow-up
period and perhaps also after interventions in very early infec-
tion. Furthermore, as the influx of CD8þ T cells into the colon
flow cytometry. Cumulative data of the relative frequencies of the
3þCD4 lymphocytes in HCs and HIV-infected patients is shown.in HIV infection may influence cell proportions,13,28–30 thus
limiting the effectiveness of flow cytometry, measurement of
Va7.2-Ja33 mRNA or gDNA may provide a sensitive method
www.md-journal.com | 5
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FIGURE 4. Depletion of Va7.2-Ja33 gDNA in HIV infection. The
relative abundance of Va7.2-Ja33 gDNA in the PBMCs of HC
(n¼10) was correlated with the (A) abundance of Va7.2-Ja33
mRNA and with the (B) frequency of Va7.2þCD161þþCD3þ
cells. Spearman correlations were determined. (C) The relative
abundance of Va7.2-Ja33 gDNA in whole blood of HC (open
circles) and HIV-infected patients (filled circles) was compared. (D)
CT values for Va7.2-Ja33 in HC and HIV-infected patients are also
shown. The specificity of the PCR was confirmed by assessing the
relative abundance of Va7.2-Ja33 (E) mRNA and (F) gDNA in
sorted MAIT cell (Va7.2þCD161þþCD3þCD8þ) and non-MAIT
cell (Va7.2CD161CD3þ) populations. gDNA¼genomic
Ussher et alfor measuring MAIT cell dynamics in the tissues during HIV
infection and treatment.
A limitation of our study is that our assay does not assess
the abundance of Va7.2-Ja12 and Va7.2-Ja20 MAIT cells.
Although Va7.2-Ja33 MAIT cells form the overwhelming
majority of the blood MAIT cell population in most people,
Va7.2-Ja12 and Va7.2-Ja20 MAIT cells can comprise up to
50% in some individuals.10,31 Va7.2-Ja12 MAIT cells also
appear to be enriched in some tissues, although in most donors
Va7.2-Ja33MAIT cells still predominate.31 Nonetheless, given
that Va7.2-Ja12, Va7.2-Ja20, and Va7.2-Ja33 MAIT cell
TCRs all bind to ligand-bound MR1,10 there is no a priori
reason to hypothesize that different subsets are differentially
DNA, HC¼healthy control, MAIT¼mucosal-associated invariant
T, mRNA¼messenger RNA, PBMC¼peripheral blood mono-
nuclear cell, PCR¼polymerase chain reaction.depleted in HIV infection compared with HCs. Therefore,
although our analysis only involves a single Ja segment, it is
the most abundant in the majority of individuals and the
6 | www.md-journal.comconclusions drawn could reasonably be expected to be
applicable to MAIT cells containing alternative Ja segments
(Ja12 and Ja20). The fate of alternative MAIT cell populations
should be investigated in future studies.
The loss of MAIT cells in HIV may contribute to immu-
nodeficiency. In vivo animal models suggest that MAIT cells
have a nonredundant role in controlling systemic and mucosal
infection with a range of bacteria, including BCG and Enter-
obacteriaceae.7,8,32,33 Given the increased rate of progression to
active tuberculosis following infection with M tuberculosis34
and the high rates of invasive nontyphoidal Salmonella infec-
tion in HIV infection,35 it will be important to determine the role
of MAIT cell depletion in HIV-induced immunodeficiency.
In conclusion, through the measurement of Va7.2-Ja33
mRNA and gDNA levels, we have confirmed that MAIT cells
are depleted from the blood in HIV infection and that significant
accumulation of a CD161 MAIT cell population is unlikely.
Future studies to investigate the fate of MAIT cells in tissue in
HIV infection, using these techniques, are warranted.
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